AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
Log in

NASDAQ:MYOKMyokardia Stock Price, Forecast & News

$103.95
+0.93 (+0.90 %)
(As of 06/2/2020 10:11 AM ET)
Add
Compare
Today's Range
$102.51
Now: $103.95
$103.95
50-Day Range
$52.58
MA: $80.61
$121.69
52-Week Range
$42.65
Now: $103.95
$126.30
Volume3,021 shs
Average Volume1.30 million shs
Market Capitalization$4.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Read More
Myokardia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$8.79 per share

Profitability

Net Income$-276,210,000.00

Miscellaneous

Employees165
Market Cap$4.85 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Myokardia (NASDAQ:MYOK) Frequently Asked Questions

How has Myokardia's stock been impacted by COVID-19 (Coronavirus)?

Myokardia's stock was trading at $55.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MYOK stock has increased by 86.0% and is now trading at $103.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Myokardia?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myokardia.

When is Myokardia's next earnings date?

Myokardia is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Myokardia.

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) posted its earnings results on Wednesday, May, 6th. The biotechnology company reported ($1.50) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by $0.14. View Myokardia's earnings history.

What price target have analysts set for MYOK?

11 analysts have issued 1 year price objectives for Myokardia's stock. Their forecasts range from $86.00 to $188.00. On average, they expect Myokardia's share price to reach $126.44 in the next year. This suggests a possible upside of 21.6% from the stock's current price. View analysts' price targets for Myokardia.

Has Myokardia been receiving favorable news coverage?

News headlines about MYOK stock have trended very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myokardia earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutMyokardia.

Who are some of Myokardia's key competitors?

What other stocks do shareholders of Myokardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include Micron Technology (MU), NVIDIA (NVDA), CVS Health (CVS), Exelixis (EXEL), Alibaba Group (BABA), Johnson & Johnson (JNJ), Verizon Communications (VZ), AbbVie (ABBV), Gilead Sciences (GILD) and AT&T (T).

Who are Myokardia's key executives?

Myokardia's management team includes the following people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)
  • Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)
  • Dr. Charles J. Homcy, Advisor (Age 71)
  • Dr. Eric J. Topol, Advisor (Age 65)

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

Who are Myokardia's major shareholders?

Myokardia's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.86%), Wellington Management Group LLP (6.64%), Janus Henderson Group PLC (3.27%), Perceptive Advisors LLC (2.82%), Casdin Capital LLC (2.13%) and State Street Corp (2.11%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Cynthia J Ladd, Jake Bauer, June Lee, Marc Semigran, Sanofi, Taylor C Harris and William Fairey. View institutional ownership trends for Myokardia.

Which major investors are selling Myokardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Primecap Management Co. CA, Pictet Asset Management Ltd., Spark Investment Management LLC, WINTON GROUP Ltd, Rhenman & Partners Asset Management AB, AXA, and Castleark Management LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Cynthia J Ladd, Jake Bauer, June Lee, Taylor C Harris, and William Fairey. View insider buying and selling activity for Myokardia.

Which major investors are buying Myokardia stock?

MYOK stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vivo Capital LLC, Two Sigma Advisers LP, Perceptive Advisors LLC, Wells Fargo & Company MN, Two Sigma Investments LP, Squarepoint Ops LLC, and Morgan Stanley. View insider buying and selling activity for Myokardia.

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $103.95.

How big of a company is Myokardia?

Myokardia has a market capitalization of $4.85 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-276,210,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis. Myokardia employs 165 workers across the globe.

What is Myokardia's official website?

The official website for Myokardia is www.myokardia.com.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.